Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticleOncology Briefs

Targeted cancer therapies

Clinical pearls for primary care

Sian L. Shuel
Canadian Family Physician July 2022; 68 (7) 515-518; DOI: https://doi.org/10.46747/cfp.6807515
Sian L. Shuel
General practitioner in oncology in Abbotsford, BC, and Medical Education Lead of BC Cancer’s Primary Care Program.
MD CCFP(PC) FCFP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Patients often have questions about their cancer diagnoses and treatment options. Family physicians are well situated in the health care system to help patients navigate this landscape, but to do this effectively they need to understand emerging cancer treatment options.

There are currently 4 general types of systemic therapy options for cancer treatment: chemotherapy, immunotherapy, endocrine therapy, and targeted therapy, with some overlap among the categories. For example, although immunotherapies are a form of targeted therapy, immunotherapy is a distinct class.1

Genetic mutations and resultant changes in cellular proteins can cause cells to divide too rapidly, resulting in malignant growth.2 To create a targeted therapy, researchers identify the potential genetic mutations and resultant abnormal proteins that drive the growth of certain types of cancer. The targeted therapy drug affects only the abnormal protein, in contrast to chemotherapy, which is nonselective and affects all rapidly dividing cells.3 Targeted therapies work only if the cancer has the target in question, and many cancers develop resistance to these agents over time. In addition to the cancer type and subtype being identified, potential molecular targets are found by testing the tumour sample for overexpression of biomarkers or for mutations causing cells to multiply rapidly. Identifying these specific targets helps determine management options.

Depending on the specific molecular targets, targeted therapy can act on cell surface antigens, growth factors, receptors, or signal transduction pathways that regulate cell cycle progression, cell death, metastasis, and angiogenesis (Figure I).4,5 While most targeted therapies are either monoclonal antibodies or small-molecule drugs, they can also be classified as hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules.3 Drugs used in molecular targeted therapy can block signals that favour the promotion of cancer cell growth, interfere with the regulation of the cell cycle, or induce cell death to kill the cancer cells.

Figure 1.
  • Download figure
  • Open in new tab
Figure 1.

Targets for molecularly targeted cancer therapy

Types of targeted therapy

The 2 most common types of targeted therapy are monoclonal antibodies and small-molecule inhibitors. Monoclonal antibodies target specific proteins, often receptors, on the cancer cell’s surface6 or in the environment around the tumour. These large molecules are not able to enter the cell. They can prevent cancer cell proliferation by blocking molecules that signal cancer cell growth or angiogenesis.

Monoclonal antibodies can be linked to a toxic substance, such as standard chemotherapy or radionuclides, to deliver the therapy to the cancer cells.1 Brentuximab vedotin7 (used in treating Hodgkin lymphoma and some other lymphomas) is an example of a monoclonal antibody-drug conjugate.

Clinical pearl: The names of monoclonal antibodies often end in -mab (eg, rituximab, bevacizumab, trastuzumab, pertuzumab, panitumumab).

The other common type of targeted therapy is small-molecule drugs, which, owing to their low molecular weight, pass through the cell surface to intracellular targets to slow proliferation or cause tumour cell death.

Clinical pearl: The names of small-molecule drugs often end in -mib (for protease inhibitors) or -nib (for kinase inhibitors),8 such as bortezomib, osimertinib, and vemurafenib.

Examples of commonly used targeted therapies

An overexpression of the human epidermal growth factor receptor 2 (HER2) gene (now known as erb-b2 receptor tyrosine kinase 2 [ERBB2]) exists in HER2 mutation–positive breast cancers and gastric cancers. The monoclonal antibodies trastuzumab and pertuzumab can be used to treat HER2 mutation-positive breast cancers and target different regions of HER2.9 Trastuzumab emtansine is an example of a monoclonal antibody–drug conjugate used to treat breast cancer that targets HER2 and delivers the cytotoxic drug to tumour cells.10

Cyclin-dependent kinase 4 and cyclin-dependent kinase 6 inhibitors (eg, palbociclib, ribociclib) are used to treat hormone receptor–positive, HER2 mutation–negative breast cancers.

Poly(adenosine diphosphate ribose) polymerase inhibitors (eg, olaparib, niraparib) target an enzyme that repairs DNA damage and are used to treat some ovarian cancers.11,12 Olaparib is also indicated in BRCA mutation–positive breast cancer treatment.

In non-small cell lung cancers, epidermal growth factor receptor (EGFR) mutation–positive tumours exhibit rapid cell division and growth; EGFR tyrosine kinase inhibitors (eg, osimertinib, gefitinib, erlotinib) are small-molecule drugs that target EGFR mutation–positive tumours. Another protein targeted in treating non-small cell lung cancer is anaplastic lymphoma kinase (ALK). Cells with ALK mutations can be targeted by ALK inhibitors (eg, crizotinib). There are several other potential molecular targets noted in non–small cell lung cancers.

Treatment of colorectal cancer may include bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits the growth of tumour blood vessels.13 Panitumumab, another monoclonal antibody, targets EGFR. Since mutations in the Kirsten rat sarcoma virus gene may be associated with reduced effectiveness of panitumumab, testing for these mutations is indicated.

Approximately half of melanomas have mutations in the B-type Raf proto-oncogene (BRAF),14 resulting in an altered BRAF protein that promotes cancer cell growth. B-type Raf proto-oncogene protein inhibitors (eg, vemurafenib, dabrafenib) are small-molecule targeted therapies that can be effective against BRAF mutation-positive cancers. Mitogen-activated protein kinase inhibitors (eg, trametinib) can also work against BRAF mutation-positive melanomas and can be combined with BRAF inhibitors.

Other targeted therapies worth mentioning are rituximab, a monoclonal antibody that targets the CD20 pathway and is commonly used to treat certain types of lymphoma and chronic lymphocytic leukemia15; daratumumab, which is used in the treatment of multiple myeloma and targets CD3816; and bortezomib, which is used to treat multiple myeloma and some lymphomas.17 Sunitinib is a tyrosine kinase inhibitor used to treat renal cell cancer.18

Targeted therapy administration

Most small-molecule drugs are conveniently formulated as tablets or capsules, whereas most monoclonal antibodies are administered intravenously. However, some monoclonal antibodies, such as rituximab,15 can be given subcutaneously if no contraindication exists, allowing for shortened treatment day times. Trastuzumab is also given subcutaneously in some remote areas, resulting in less travel and less time away from home for patients.

Side effects

Despite the expectation that targeted therapy would have fewer adverse effects than traditional chemotherapy, substantial toxicities are still seen. These targeted therapy toxicities differ from those seen with chemotherapy and vary according to the targeted therapy’s mechanism of action. Patients may present to their family physicians with these adverse effects (eg, bleeding), and oncologists may enlist family physicians’ help in patients’ ongoing side effect management (eg, hypertension). Skin problems are commonly seen with EGFR inhibitors and can consist of acneiform rash (Figure 2),19 nail changes (Figure 3),19 hair discolouration, dry skin, and yellow discolouration of the skin.18 Box 1 summarizes preventive measures and considerations for managing rash associated with EGFR inhibitor use.20 Congestive heart failure is a known adverse effect of trastuzumab. Side effects commonly seen with VEGF inhibitors and VEGF receptor inhibitors include hypertension, thromboembolic events, impaired wound healing, and increased risk of bleeding (including tumour-associated hemorrhage).21

Figure 2.
  • Download figure
  • Open in new tab
Figure 2. Acneiform eruption seen with epidermal growth factor receptor inhibitor use:

A) Papular lesions on the chest, B) V-shaped papulopustular eruption on the back, C) close-up of follicular pustules, and D) confluent pustules on the nose.

Figure 3.
  • Download figure
  • Open in new tab
Figure 3.

Paronychia and pyogenic granuloma of the nail fold of the big toe caused by epidermal growth factor receptor inhibitor use

Box 1.

Addressing rash associated with EGFR inhibitor use

Preventive measures for rash associated with EGFR inhibitor use can include assessing patients for skin conditions such as acne, rosacea, and psoriasis that can worsen with EGFR inhibitors.20 Education around moisturizing, avoiding excessive sun exposure, wearing a hat and long sleeves, and using sunscreen is important.

Prophylaxis (eg, with minocycline 100 mg by mouth twice daily and hydrocortisone cream, 1%, at bedtime for the first 6 weeks followed by a taper) can be initiated.

Management of the rash can include a topical lotion with clindamycin, 2%, and hydrocortisone, 1%, twice daily with or without minocycline 100 mg by mouth twice daily, or doxycycline 100 mg twice daily for 4 weeks with or without prednisone 0.5 mg/kg by mouth once daily for 7 to 14 days, depending on the severity of the rash. Also:

  • Obtaining a bacterial culture for secondary infection is recommended for severe rashes (grade 3 or higher).

  • Consider referral to a dermatologist if there is no improvement after 4 weeks.

  • Therapy dose modification or interruption may need to be considered.

  • Management should include input from the patient’s medical oncologist.

EGFR—epidermal growth factor receptor.

Treatment of side effects

Management of side effects often depends on severity. Mild adverse effects can often be treated symptomatically, while moderate effects may require a treatment break or dose reduction. Severe side effects are more likely to require ceasing the use of the offending agent and looking for alternative treatment options.

Conclusion

As the number of new cancer diagnoses rises22 and cancer treatment options rapidly emerge, family physicians are likely to find themselves helping patients navigate questions about treatment options. Understanding how targeted therapy works, why specific therapies may or may not be options, and what adverse effects are possible is essential to helping patients navigate their cancer care journeys.

Footnotes

  • Competing interests

    Dr Sian L. Shuel receives contract support from BC Cancer as Medical Education Lead for BC Cancer’s Primary Care Program.

  • This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to https://www.cfp.ca and click on the Mainpro+ link.

  • La traduction en français de cet article se trouve à https://www.cfp.ca dans la table des matières du numéro de juillet 2022 à la page e199.

  • Copyright © 2022 the College of Family Physicians of Canada

References

  1. 1.↵
    1. Dahan R.
    Monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. New York, NY: Cancer Research Institute; 2021. Available from: https://www.cancerresearch.org/immunotherapy/treatment-types/targeted-antibodies. Accessed 2022 Jan 21.
  2. 2.↵
    What is targeted therapy? Alexandria, VA: American Society of Clinical Oncology; 2022. Available from: https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/what-targeted-therapy? Accessed 2022 May 27.
  3. 3.↵
    What is targeted therapy? In: Targeted therapy to treat cancer. Bethesda, MD: National Cancer Institute; 2021. Available from: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet. Accessed 2022 Jan 21.
  4. 4.↵
    1. Saijo N.
    Progress in cancer chemotherapy with special stress on molecular-targeted therapy. Jpn J Clin Oncol 2010;40(9):855-62. Epub 2010 Jul 22.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Huang M,
    2. Shen A,
    3. Ding J,
    4. Geng M.
    Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci 2014;35(1):41-50. Epub 2013 Dec 19.
    OpenUrlCrossRef
  6. 6.↵
    What are the types of targeted therapy? In: Targeted therapy to treat cancer. Bethesda, MD: National Cancer Institute; 2020. Available from: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies#whatare-the-types-of-targeted-therapy. Accessed 2022 Jan 21.
  7. 7.↵
    1. Firer MA,
    2. Gellerman G.
    Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol 2012;5:70.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Scott GN.
    Sorting through the confusion of biologic drug names. Medscape 2016 Aug 19. Available from: https://www.medscape.com/viewarticle/867446_1. Accessed 2022 Jan 21.
  9. 9.↵
    1. Keating GM.
    Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs 2012;72(3):353-60.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Trastuzumab emtansine [product monograph]. Vancouver, BC: BC Cancer; 2018. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Trastuzumab%20Emtansine_monograph.pdf. Accessed 2022 Jan 21.
  11. 11.↵
    Olaparib [product monograph]. Vancouver, BC: BC Cancer; 2020. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Olaparib_monograph.pdf. Accessed 2022 Jan 28.
  12. 12.↵
    Niraparib [product monograph]. Vancouver, BC: BC Cancer; 2021. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Niraparib_monograph.pdf. Accessed 2022 Jan 28.
  13. 13.↵
    1. Shih T,
    2. Lindley C.
    Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28(11):1779-802.
    OpenUrlCrossRefPubMed
  14. 14.↵
    Targeted therapy drugs for melanoma skin cancer. Atlanta, GA: American Cancer Society; 2019. Available from: https://www.cancer.org/cancer/melanoma-skin-cancer/treating/targeted-therapy.html. Accessed 2022 Jan 21.
  15. 15.↵
    Rituximab [product monograph]. Vancouver, BC: BC Cancer; 2021. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Rituximab_monograph.pdf. Accessed 2022 Jan 21.
  16. 16.↵
    Daratumumab [product monograph]. Vancouver, BC: BC Cancer; 2019. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Daratumumab_monograph.pdf. Accessed 2022 Jan 21.
  17. 17.↵
    Bortezomib [product monograph]. Vancouver, BC: BC Cancer; 2021. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Bortezomib_monograph.pdf. Accessed 2022 Jan 21.
  18. 18.↵
    Sunitinib [product monograph]. BC Cancer drug manual. Vancouver, BC: BC Cancer; 2019. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Sunitinib_monograph.pdf. Accessed 2022 Jan 21.
  19. 19.↵
    1. Segaert S,
    2. Van Cutsem E.
    Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16(9):1425-33. Epub 2005 Jul 12.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Prevention and treatment of acneiform rash in patients treated with EGFR inhibitor therapies. Edmonton, AB: Cancer Care Alberta; 2020. Available from: https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-supp003-egfri-rash.pdf. Accessed 2022 Jan 21.
  21. 21.↵
    Bevacizumab [product monograph]. Vancouver, BC: BC Cancer; 2021. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Bevacizumab_monograph.pdf. Accessed 2022 Jan 21.
  22. 22.↵
    Canadian Cancer Statistics Advisory Committee, Canadian Cancer Society, Statistics Canada, Public Health Agency of Canada. Canadian cancer statistics 2021. Toronto, ON: Canadian Cancer Society; 2021. Available from: https://cancer.ca/Canadian-Cancer-Statistics-2021-EN. Accessed 2022 Jan 21.
PreviousNext
Back to top

In this issue

Canadian Family Physician: 68 (7)
Canadian Family Physician
Vol. 68, Issue 7
1 Jul 2022
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Targeted cancer therapies
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Targeted cancer therapies
Sian L. Shuel
Canadian Family Physician Jul 2022, 68 (7) 515-518; DOI: 10.46747/cfp.6807515

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Targeted cancer therapies
Sian L. Shuel
Canadian Family Physician Jul 2022, 68 (7) 515-518; DOI: 10.46747/cfp.6807515
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Types of targeted therapy
    • Examples of commonly used targeted therapies
    • Targeted therapy administration
    • Side effects
    • Treatment of side effects
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • Therapies ciblées contre le cancer
  • PubMed
  • Google Scholar

Cited By...

  • Targeting Colorectal Cancer Liver Metastasis Through Repurposing Metabolic and Immune Inhibitors : A Theoretical Study
  • Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery
  • Cancer survivorship road map
  • Feuilles de route de la survivance au cancer
  • Google Scholar

More in this TOC Section

  • Having hard conversations
  • Cardiotoxicity of cancer treatment
  • Cancer survivorship road map
Show more Oncology Briefs

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire